Kymera Therapeutics, Inc. Common Stock vs. TScan Therapeutics, Inc. Common Stock
KYMR
Kymera Therapeutics, Inc. Common Stock
$117.39 +2.60%
VS TCRXTScan Therapeutics, Inc. Common Stock
$0.78 +0.88%
Kymera Therapeutics, Inc. Common Stock and TScan Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| KYMR | TCRX | |
|---|---|---|
| Market Cap | $9.48 billion | $52.39 million |
| Revenue (TTM) | $105.00 million | $7.11 million |
| Net Income (TTM) | $-299,601,000 | $-117,712,000 |
KYMR leads on 2 of 3 size & scale factors.
Valuation
| KYMR | TCRX | |
|---|---|---|
| Price / Book | 6.28 | 0.76 |
| Price / Sales | 90.30 | 7.37 |
TCRX leads on 2 of 2 valuation factors.
Profitability
| KYMR | TCRX | |
|---|---|---|
| Net Margin | -285.34% | -1655.35% |
| Return on Equity | -19.85% | -170.55% |
KYMR leads on 2 of 2 profitability factors.
Risk & Sentiment
| KYMR | TCRX | |
|---|---|---|
| Short Interest | 0.24% | 0.01% |
TCRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: KYMR overview, KYMR financials, TCRX overview, TCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.